Sambrook P N
University of Sydney, Royal North Shore Hospital, Australia.
J Bone Miner Res. 2000 Sep;15(9):1645-9. doi: 10.1359/jbmr.2000.15.9.1645.
Corticosteroids are widely used and effective agents for control of many inflammatory diseases, but osteoporosis is a common problem associated with their long-term use. Several large double-blind controlled clinical trials in patients with corticosteroid osteoporosis recently have been published, indicating it is possible to prevent or reverse this bone loss. Ultimately, the aim of treatment is to prevent fractures, especially vertebral fractures that are the most common type of fracture associated with corticosteroid therapy, yet it remains unclear exactly which patients should receive prophylaxis. Understanding the differences between these trials is key to interpreting the results, which have important practical implications for patient management.
皮质类固醇是广泛使用且有效的控制多种炎症性疾病的药物，但骨质疏松是与其长期使用相关的常见问题。最近已发表了几项针对皮质类固醇性骨质疏松患者的大型双盲对照临床试验，表明有可能预防或逆转这种骨质流失。最终，治疗的目的是预防骨折，尤其是椎体骨折，这是与皮质类固醇治疗相关的最常见骨折类型，但仍不清楚究竟哪些患者应接受预防治疗。了解这些试验之间的差异是解释结果的关键，这些结果对患者管理具有重要的实际意义。
